GlaxoSmithKline R&D, Medicines Research Centre, Gunnels Wood Road, Stevenage, Hertfordshire SG1 2NY, UK.
Bioorg Med Chem Lett. 2011 May 15;21(10):3037-40. doi: 10.1016/j.bmcl.2011.03.038. Epub 2011 Mar 21.
Heteroalicyclic carboxamidines were synthesised and evaluated as inhibitors of nitric oxide synthases. (2R)-2-Pyrrolidinecarboxamidine, in particular, was shown to be a highly potent in vitro (IC(50)=0.12 μM) and selective iNOS inhibitor (>100-fold vs both eNOS and nNOS), with probable binding to the key anchoring glutamate residue and co-ordination to the haem iron.
杂环羧脒被合成并评估为一氧化氮合酶抑制剂。特别是(2R)-2-吡咯烷甲脒,被证明是一种高效的体外(IC50=0.12 μM)和选择性 iNOS 抑制剂(对 eNOS 和 nNOS 的抑制作用超过 100 倍),可能与关键的锚定谷氨酸残基结合,并与血红素铁配位。